FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology, more specifically to a monoclonal antibody (mAb), and can be used in medicine. The above antibody binds to the fibroblast growth factor receptor 2-IIIb (FGFR2IIIb) and contains three CDRs of the light chain and three CDR of the heavy chain presented in Fig.13A and 13B, respectively. The engineered antibody or its humanised analogue is used as an ingredient of a pharmaceutical composition for treating a malignant disease.
EFFECT: invention enables producing the anti-FGFR2IIIb antibody promoting the most effective and complete inhibition of the human tumour heterograft growth in mice.
12 cl, 16 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AFUCOSYLATED FGFR2IIIB FIBROBLAST GROWTH FACTOR RECEPTOR | 2014 |
|
RU2698061C2 |
| FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN CANCER TREATMENT | 2016 |
|
RU2745707C2 |
| AFUCOSYLATED FIBROBLAST GROWTH FACTOR FGFR2IIIB RECEPTOR | 2014 |
|
RU2740714C2 |
| ANTIBODIES TO FGFR2 IN COMBINATION WITH CHEMOTHERAPY IN CANCER TREATMENT | 2018 |
|
RU2797560C2 |
| HUMANISED ANTIBODIES TO LIV-1 AND USE THEREOF FOR TREATING CANCER | 2011 |
|
RU2608646C2 |
| HUMANISED MONOCLONAL ANTIBODIES TO HEPATOCYTE GROWTH FACTOR | 2007 |
|
RU2461570C2 |
| EXTRACELLULAR DOMAIN OF TYROSINE KINASE RECEPTOR, ALLOSTERIC BINDING INHIBITOR | 2010 |
|
RU2604805C2 |
| INTERLEUKIN-13-BINDING PROTEINS | 2012 |
|
RU2605327C2 |
| INTERLEUKIN-13-BINDING PROTEINS | 2016 |
|
RU2650767C2 |
| IMMUNOGLOBULIN WITH DOUBLE VARIABLE DOMAINS AND ITS APPLICATIONS | 2006 |
|
RU2515108C2 |
